Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact
Rajalakshmi Govalan, Michael Luu, Marie Lauzon, Kambiz Kosari, Joseph C. Ahn, Nicole E Rich, Nicholas Nissen, Lewis R. Roberts, Amit G. Singal, Ju Dong Yang – 24 August 2021 – Prognosis of hepatocellular carcinoma (HCC) could be affected by lack of or delayed therapy. We aimed to characterize the prevalence, correlates, and clinical impact of therapeutic underuse and delay in patients with HCC. Patients with HCC diagnosed between 2010 and 2017 were analyzed from the United States National Cancer Database.